Stockscreener 앱 받기
1.32
3.94%
0.05
시간 외 거래:
1.30
-0.02
-1.52%
전일 마감가:
$1.27
열려 있는:
$1.255
하루 거래량:
58,999
Relative Volume:
0.41
시가총액:
$45.38M
수익:
-
순이익/손실:
$-10.41M
주가수익비율:
-3.9274
EPS:
-0.3361
순현금흐름:
$-3.69M
1주 성능:
-5.71%
1개월 성능:
+16.81%
6개월 성능:
-13.73%
1년 성능:
-69.66%
1일 변동 폭
$1.2301
$1.32
1주일 범위
$1.2001
$1.40
52주 변동 폭
$1.05
$4.805
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
명칭
Telomir Pharmaceuticals Inc
전화
786-396-6723
주소
100 SE 2ND ST, MIAMI
Compare TELO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
1.32 | 43.66M | 0 | -10.41M | -3.69M | -0.3361 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-21 | 개시 | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc 주식(TELO)의 최신 뉴스
CEO Moves: Is Telomir Pharmaceuticals Inc stock good for income investors2026 Stock Rankings & Risk Managed Investment Signals - baoquankhu1.vn
Telomir Pharmaceuticals, Inc.: Preclinical Pipeline Targeting Aging and Age-Related Diseases with Novel Small-Molecule Therapeutics - Minichart
Insider Buy: How does Telomir Pharmaceuticals Inc score in quality rankingsMarket Rally & Real-Time Volume Triggers - baoquankhu1.vn
Telomir Pharmaceuticals 2025 10-K: $0 Revenue, $(0.33) EPS on $(10.41)M Net Loss - TradingView
US Market Recap: Will Unisys Corporation stock go up in YEAR2026 Short Interest & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Winners Losers: Is Telomir Pharmaceuticals Inc a top pick in the sectorTrade Risk Summary & Growth Oriented Trade Recommendations - baoquankhu1.vn
Risk Analysis: Can Genco Shipping Trading Limited be recession proofWall Street Watch & Daily Stock Momentum Reports - baoquankhu1.vn
Trading Action: Is Telomir Pharmaceuticals Inc. a good ESG investmentQuarterly Growth Report & Short-Term High Return Ideas - baoquankhu1.vn
Portfolio Recap: Will Telomir Pharmaceuticals Inc outperform small cap indexesJuly 2025 Update & Entry Point Confirmation Signals - baoquankhu1.vn
Nasdaq Moves: Is Telomir Pharmaceuticals Inc a good ESG investment2025 Momentum Check & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
TELO Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models - ACCESS Newswire
TELO Technical Analysis & ETF Price Forecast - Intellectia AI
Telomir Pharmaceuticals Inc. (TELO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development - Coshocton Tribune
Activity Recap: Is Telomir Pharmaceuticals Inc stock influenced by commodity pricesCPI Data & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Valuation Update: What are the risks of holding Telomir Pharmaceuticals IncJuly 2025 Selloffs & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
Telomir Pharmaceuticals Faces Crucial Corporate and Regulatory Deadlines () - aktiencheck.de
Telomir Pharmaceuticals (NASDAQ:TELO) Stock Rating Upgraded by Wall Street Zen - Defense World
Is Telomir Pharmaceuticals Inc. stock a good dividend stockJuly 2025 Gainers & Verified Chart Pattern Signals - mfd.ru
Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 4.2% – Should You Sell? - Defense World
Telomir Sets Vote on Transformative TELI Merger and Governance Changes - The Globe and Mail
Telomir reveals promising preclinical data for Telomir-Zn - TipRanks
Telomir Pharmaceuticals demonstrates broad tumor cell mortality in human triple-negative breast cancer models - marketscreener.com
Telomir Pharmaceuticals Inc's latest research shows that the company has achieved extensive tumor cell death rates in human triple-negative breast cancer experimental models. - Bitget
Telomir Pharmaceuticals, Inc. Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models - marketscreener.com
Telomir (NASDAQ: TELO) posts new Telomir-1 preclinical data in triple-negative breast cancer - Stock Titan
Experimental breast cancer drug triggers iron-dependent tumor cell death - Stock Titan
Investment Report: What are the risks of holding Telomir Pharmaceuticals IncJuly 2025 Technicals & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
What are the risks of holding Telomir Pharmaceuticals Inc.Trade Exit Summary & Entry Point Confirmation Signals - mfd.ru
Is Telomir Pharmaceuticals Inc. a top pick in the sectorTrade Signal Summary & Weekly Momentum Picks - mfd.ru
Will Telomir Pharmaceuticals Inc. stock benefit from upcoming earnings reportsEarnings Growth Report & Community Supported Trade Ideas - mfd.ru
John Paul DeJoria holds 9.4% of Telomir (TELO) common stock - Stock Titan
Can Telomir Pharmaceuticals Inc. stock attract ESG capital inflowsJuly 2025 Sentiment & Precise Swing Trade Alerts - mfd.ru
Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging - ACCESS Newswire
What are the risks of holding Telomir Pharmaceuticals IncChart Signals & Daily Growth Stock Investment Tips - baoquankhu1.vn
Telomir Pharmaceuticals Highlights Preclinical Data for Telomir-1 - TipRanks
Experimental Telomir-Zn compound rebalances metals tied to cancer and aging - Stock Titan
Telomir Pharmaceuticals Reports New Cellular Data on Epigenetic Modulation - TradingView
Setup Watch: Can Telomir Pharmaceuticals Inc outperform under higher oil pricesJuly 2025 Selloffs & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
US Market Wrap: Is SIGA in a consolidation phasePortfolio Update Summary & Low Drawdown Investment Strategies - baoquankhu1.vn
Is Telomir Pharmaceuticals Inc. a cyclical or defensive stockJuly 2025 Review & Growth Focused Stock Reports - mfd.ru
Insider Buy: How does Telomir Pharmaceuticals Inc compare to its peersRate Hike & Daily Profit Focused Screening - baoquankhu1.vn
Stock Analysis: How volatile is Telomir Pharmaceuticals Inc stockQuarterly Performance Summary & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Market Outlook: Is Telomir Pharmaceuticals Inc a cyclical or defensive stockWeekly Gains Report & Stepwise Trade Execution Plans - baoquankhu1.vn
Financial Survey: Telomir Pharmaceuticals (NASDAQ:TELO) versus electroCore (NASDAQ:ECOR) - Defense World
Gainers Report: What are the risks of holding Telomir Pharmaceuticals Inc2025 Stock Rankings & Daily Stock Trend Reports - baoquankhu1.vn
Will Telomir Pharmaceuticals Inc outperform small cap indexesJuly 2025 Review & Low Risk Entry Point Tips - baoquankhu1.vn
How does Telomir Pharmaceuticals Inc. compare to its peersJuly 2025 Weekly Recap & Technical Pattern Based Signals - bollywoodhelpline.com
Rodman & Renshaw initiates Telomir Pharma stock with Buy rating By Investing.com - Investing.com Canada
Aug Shorts: Is ImmuCell Corporation forming a bullish divergenceEarnings Overview Summary & Weekly Stock Breakout Alerts - baoquankhu1.vn
Telomir Pharmaceuticals Inc (TELO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):